546 lines
No EOL
136 KiB
HTML
546 lines
No EOL
136 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK606100" /><meta name="ncbi_domain" content="statpearls" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK606100/" /><meta name="ncbi_pagename" content="Angiotensin Receptor Blockers and HCTZ Combination Drugs - StatPearls - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Angiotensin Receptor Blockers and HCTZ Combination Drugs - StatPearls - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="StatPearls [Internet]" /><meta name="citation_title" content="Angiotensin Receptor Blockers and HCTZ Combination Drugs" /><meta name="citation_publisher" content="StatPearls Publishing" /><meta name="citation_date" content="2024/08/16" /><meta name="citation_author" content="Sheeba Sagar" /><meta name="citation_author" content="Preeti Patel" /><meta name="citation_pmid" content="39163455" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK606100/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Angiotensin Receptor Blockers and HCTZ Combination Drugs" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="StatPearls Publishing" /><meta name="DC.Contributor" content="Sheeba Sagar" /><meta name="DC.Contributor" content="Preeti Patel" /><meta name="DC.Date" content="2024/08/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK606100/" /><meta name="description" content="Systemic hypertension is a condition that poses a significant risk of complications for patients with cardiovascular disease and contributes significantly to all-cause mortality worldwide. Hypertension is a preventable and modifiable risk factor, and controlling blood pressure often requires 2 or more antihypertensive agents. Combining angiotensin receptor blockers (ARBs) and hydrochlorothiazide (HCTZ) effectively controls blood pressure due to synergistic action. Widespread uncontrolled hypertension due to poor medication adherence led to the development of single-pill combination medications to improve compliance. This activity discusses the indications, mechanisms of action, adverse effects, contraindications, and drug interactions of combination ARB-HCTZ therapy. Understanding effective management practices is crucial for interprofessional teams providing care to patients with hypertension, helping more patients achieve blood pressure targets and improved outcomes." /><meta name="og:title" content="Angiotensin Receptor Blockers and HCTZ Combination Drugs" /><meta name="og:type" content="book" /><meta name="og:description" content="Systemic hypertension is a condition that poses a significant risk of complications for patients with cardiovascular disease and contributes significantly to all-cause mortality worldwide. Hypertension is a preventable and modifiable risk factor, and controlling blood pressure often requires 2 or more antihypertensive agents. Combining angiotensin receptor blockers (ARBs) and hydrochlorothiazide (HCTZ) effectively controls blood pressure due to synergistic action. Widespread uncontrolled hypertension due to poor medication adherence led to the development of single-pill combination medications to improve compliance. This activity discusses the indications, mechanisms of action, adverse effects, contraindications, and drug interactions of combination ARB-HCTZ therapy. Understanding effective management practices is crucial for interprofessional teams providing care to patients with hypertension, helping more patients achieve blood pressure targets and improved outcomes." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK606100/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/statpearls/article-160212/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK606100/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CF7047C8067510000000000490033.m_13" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
<div id="universal_header">
|
||
<section class="usa-banner">
|
||
<div class="usa-accordion">
|
||
<header class="usa-banner-header">
|
||
<div class="usa-grid usa-banner-inner">
|
||
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
||
<p>An official website of the United States government</p>
|
||
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
||
<span class="usa-banner-button-text">Here's how you know</span>
|
||
</button>
|
||
</div>
|
||
</header>
|
||
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
||
<div class="usa-banner-guidance-gov usa-width-one-half">
|
||
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
||
<div class="usa-media_block-body">
|
||
<p>
|
||
<strong>The .gov means it's official.</strong>
|
||
<br />
|
||
Federal government websites often end in .gov or .mil. Before
|
||
sharing sensitive information, make sure you're on a federal
|
||
government site.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
||
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
||
<div class="usa-media_block-body">
|
||
<p>
|
||
<strong>The site is secure.</strong>
|
||
<br />
|
||
The <strong>https://</strong> ensures that you are connecting to the
|
||
official website and that any information you provide is encrypted
|
||
and transmitted securely.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
<div class="usa-overlay"></div>
|
||
<header class="ncbi-header" role="banner" data-section="Header">
|
||
|
||
<div class="usa-grid">
|
||
<div class="usa-width-one-whole">
|
||
|
||
<div class="ncbi-header__logo">
|
||
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
||
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
||
</a>
|
||
</div>
|
||
|
||
<div class="ncbi-header__account">
|
||
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
||
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
||
<span class="fa fa-user" aria-hidden="true">
|
||
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
||
<g style="fill: #fff">
|
||
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
||
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
||
</g>
|
||
</svg>
|
||
</span>
|
||
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
||
<span class="sr-only">Show account info</span>
|
||
</button>
|
||
</div>
|
||
|
||
<div class="ncbi-popup-anchor">
|
||
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
||
<div class="ncbi-popup-head">
|
||
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
||
<span class="fa fa-times">
|
||
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
||
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
||
</svg>
|
||
</span>
|
||
<span class="usa-sr-only">Close</span></button>
|
||
<h4>Account</h4>
|
||
</div>
|
||
<div class="account-user-info">
|
||
Logged in as:<br />
|
||
<b><span class="username" id="uname_long">username</span></b>
|
||
</div>
|
||
<div class="account-links">
|
||
<ul class="usa-unstyled-list">
|
||
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
||
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
||
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
||
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</header>
|
||
<div role="navigation" aria-label="access keys">
|
||
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
||
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
||
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
||
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
||
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
||
</div>
|
||
<section data-section="Alerts">
|
||
<div class="ncbi-alerts-placeholder"></div>
|
||
</section>
|
||
</div>
|
||
<div class="header">
|
||
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
||
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="refseq">RefSeq</option><option value="nuccore">Nucleotide</option><option value="clinvar" class="last">ClinVar</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
||
<a href="/books/browse/">Browse Titles</a>
|
||
</li><li>
|
||
<a href="/books/advanced/">Advanced</a>
|
||
</li><li class="help">
|
||
<a href="/books/NBK3833/">Help</a>
|
||
</li><li class="disclaimer">
|
||
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
||
</li></ul></div>
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<!-- Custom content 1 -->
|
||
<div class="col1">
|
||
|
||
</div>
|
||
|
||
<div class="container">
|
||
<div id="maincontent" class="content eight_col col">
|
||
<!-- Custom content in the left column above book nav -->
|
||
<div class="col2">
|
||
|
||
</div>
|
||
|
||
<!-- Book content -->
|
||
|
||
|
||
<!-- Custom content between navigation and content -->
|
||
<div class="col3">
|
||
|
||
</div>
|
||
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/statpearls/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png" alt="Cover of StatPearls" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>StatPearls [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK606100_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK606100_dtls__"><div>Treasure Island (FL): <a href="https://www.statpearls.com/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">StatPearls Publishing</a>; 2025 Jan-.</div></div><div class="half_rhythm"></div><div class="bk_noprnt"><form method="get" action="/books/n/statpearls/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK606100_"><span class="title" itemprop="name">Angiotensin Receptor Blockers and HCTZ Combination Drugs</span></h1><p class="contrib-group"><span itemprop="author">Sheeba Sagar</span>; <span itemprop="author">Preeti Patel</span>.</p><a data-jig="ncbitoggler" href="#__NBK606100_ai__" style="border:0;text-decoration:none">Author Information and Affiliations</a><div style="display:none" class="ui-widget" id="__NBK606100_ai__"><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Sheeba Sagar</span><sup>1</sup>; <span itemprop="author">Preeti Patel</span>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> Christian Medical College, Ludhiana</div></div><p class="small">Last Update: <span itemprop="dateModified">August 16, 2024</span>.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="article-160212.s1"><h2 id="_article-160212_s1_">Continuing Education Activity</h2><p>Systemic hypertension is a condition that poses a significant risk of complications for patients with cardiovascular disease and contributes significantly to all-cause mortality worldwide. Hypertension is a preventable and modifiable risk factor, and controlling blood pressure often requires 2 or more antihypertensive agents. Combining angiotensin receptor blockers (ARBs) and hydrochlorothiazide (HCTZ) effectively controls blood pressure due to synergistic action. Widespread uncontrolled hypertension due to poor medication adherence led to the development of single-pill combination medications to improve compliance. This activity discusses the indications, mechanisms of action, adverse effects, contraindications, and drug interactions of combination ARB-HCTZ therapy. Understanding effective management practices is crucial for interprofessional teams providing care to patients with hypertension, helping more patients achieve blood pressure targets and improved outcomes.</p><p>
|
||
<b>Objectives:</b>
|
||
<ul><li class="half_rhythm"><div>Identify the indications for the single-pill angiotensin receptor blocker-hydrochlorothiazide medication.</div></li><li class="half_rhythm"><div>Assess the adverse reactions associated with angiotensin receptor blocker-hydrochlorothiazide medications.</div></li><li class="half_rhythm"><div>Evaluate the mechanism of action of angiotensin receptor blocker-hydrochlorothiazide medications.</div></li><li class="half_rhythm"><div>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from angiotensin receptor blocker-hydrochlorothiazide therapy.</div></li></ul>
|
||
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=160212&utm_source=pubmed&utm_campaign=reviews&utm_content=160212" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
||
</p></div><div id="article-160212.s2"><h2 id="_article-160212_s2_">Indications</h2><p>Hypertension contributes significantly to cardiovascular and all-cause mortality rates. Between 2017-2018, the prevalence of hypertension in adults in the U.S. was 45%, with a significant fraction of these patients belonging to older age groups.<a class="bk_pop" href="#article-160212.r1">[1]</a> The global burden of systemic hypertension continues to rise, and it is estimated that 1.6 billion people will be affected by 2025.<a class="bk_pop" href="#article-160212.r2">[2]</a> A significant number of patients with hypertension require more than 2 antihypertensive agents to achieve adequate blood pressure control. There is a significant cardiovascular benefit when drugs from different medication types are co-administered compared to increasing monotherapy doses.<a class="bk_pop" href="#article-160212.r3">[3]</a> Considering the crucial role of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of hypertension, angiotensin receptor blockers (ARB) are first-line drugs prescribed to treat hypertension. Adding a thiazide diuretic (eg, hydrochlorothiazide (HCTZ)) to the regimen improves blood pressure control through synergistic action. </p><p>Despite therapeutic advances, blood pressure control remains at unacceptable levels worldwide. To address this issue, current guidelines recommend the widespread use of combination antihypertensive therapy, specifically regimens involving fixed-dose single-pill medications. Combination antihypertensive therapy in fixed-dose combination formulations has demonstrated significant and sustained reductions in systolic and diastolic blood pressure. This approach is also associated with improved patient adherence, tolerability, and medication persistence, ultimately leading to improved blood pressure control and a reduced risk of major cardiovascular events and hospitalizations.<a class="bk_pop" href="#article-160212.r4">[4]</a><b> </b></p><p>Combining an angiotensin receptor blocker and hydrochlorothiazide (ARB-HCTZ) is the recommended initial treatment for patients requiring multiple medications to manage their blood pressure, as well as an additional therapy for patients with uncontrolled blood pressure on monotherapy. The maximum antihypertensive effect is typically observed 4 weeks after treatment initiation, with minimal to no occurrence of orthostatic hypotension.<a class="bk_pop" href="#article-160212.r5">[5]</a> The ARB-HCTZ combination effectively reduces proteinuria by inhibiting the accelerated activity of RAAS in patients with diabetic nephropathy, an off-label indication for using this medication.<a class="bk_pop" href="#article-160212.r6">[6]</a><a class="bk_pop" href="#article-160212.r7">[7]</a> The combination should be discontinued for patients who are pregnant, hypotensive, or have abnormal serum potassium levels. </p><p>According to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines, thiazide diuretics, calcium channel blockers (CCBs), and angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are recommended as first-line agents for treating hypertension.<a class="bk_pop" href="#article-160212.r8">[8]</a> Single-pill combination (SPC) antihypertensive therapies, also referred to as fixed-dose combinations (FDC), are extensively utilized for the management of elevated blood pressure. This is thought to be due to the multiple medications needed to achieve target blood pressure levels in at least 75% of patients with hypertension.<a class="bk_pop" href="#article-160212.r9">[9]</a> </p><p>According to the International Society of Hypertension (ISH) guidelines for the management of hypertension, annual screening for hypertension is recommended for all adults whenever possible. Lifestyle modifications include reducing salt intake, increasing vegetable and fruit consumption (potassium sources), appropriate weight management, and limiting alcohol consumption. ISH endorses the use of single-pill combinations to reduce pill burden.<a class="bk_pop" href="#article-160212.r9">[9]</a><a class="bk_pop" href="#article-160212.r10">[10]</a> </p><p>The 2023 European Society of Hypertension (ESH) guidelines recommend initiating therapy with a 2-drug combination for most patients with hypertension. The standard therapy typically includes a renin-angiotensin system (RAS) blocker (ACE inhibitor or ARB) combined with a CCB or a thiazide (or thiazide-like) diuretic. Antihypertensive medications, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and thiazide/thiazide-like diuretics, can prevent coronary artery disease (CAD).<a class="bk_pop" href="#article-160212.r11">[11]</a> </p><p>In a multinational retrospective cohort study comparing the real-world effectiveness and safety of ACE inhibitors versus ARBs as first-line treatment for hypertension, no statistically significant differences were observed between ACEIs and ARBs in primary outcomes like heart failure, acute myocardial infarction, stroke, or composite cardiovascular events. However, ARBs demonstrated a lower risk of secondary outcomes such as cough, angioedema, pancreatitis, and gastrointestinal bleeding. These findings suggest that ARBs may be preferable over ACE inhibitors due to their comparable effectiveness and potentially better safety profile in initiating treatment for hypertension.<a class="bk_pop" href="#article-160212.r12">[12]</a></p><p>
|
||
<b>FDA-Approved Indications</b>
|
||
</p><p>All fixed-dose ARB-HCTZ combinations are FDA-approved to treat hypertension. Additionally, losartan-hydrochlorothiazide is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.<a class="bk_pop" href="#article-160212.r13">[13]</a> This protective effect may not extend to all patients.<a class="bk_pop" href="#article-160212.r14">[14]</a> However, ARBs are beneficial for patients with comorbidities such as diabetic nephropathy or heart failure with reduced ejection fraction (HFrEF).<a class="bk_pop" href="#article-160212.r15">[15]</a> A list of single-pill combinations is provided below.</p><ul><li class="half_rhythm"><div>Valsartan and hydrochlorothiazide</div></li><li class="half_rhythm"><div>Olmesartan and hydrochlorothiazide</div></li><li class="half_rhythm"><div>Telmisartan and hydrochlorothiazide</div></li><li class="half_rhythm"><div>Irbesartan and hydrochlorothiazide</div></li><li class="half_rhythm"><div>Candesartan and hydrochlorothiazide</div></li><li class="half_rhythm"><div>Losartan and hydrochlorothiazide</div></li><li class="half_rhythm"><div>Eprosartan and hydrochlorothiazide</div></li></ul><p>
|
||
<b>Off-Label Uses</b>
|
||
</p><p>According to the AHA/ACC 2022 guidelines for heart failure, thiazide diuretics like hydrochlorothiazide may be considered in patients with hypertension, heart failure, and mild fluid retention. Inhibition of the renin-angiotensin system with angiotensin receptor neprilysin inhibitors (ARNI), ACE inhibitors, or ARB improves outcomes for patients with HFrEF.<a class="bk_pop" href="#article-160212.r15">[15]</a> According to the American Diabetes Association guidelines, combination ARBs/ACE inhibitors are first-line agents to treat patients with hypertension and diabetes, GFR <60 mL/min/1.73 m<sup>2</sup>, or a urinary albumin-to-creatinine ratio ≥300 mg albumin:g creatinine because of their established benefits for preventing CKD progression.<a class="bk_pop" href="#article-160212.r16">[16]</a> However, the potential for dysglycemia with hydrochlorothiazide administration should be taken into consideration for patients with diabetes.<a class="bk_pop" href="#article-160212.r17">[17]</a></p></div><div id="article-160212.s3"><h2 id="_article-160212_s3_">Mechanism of Action</h2><p>Excessive and inappropriate activation of the renin-angiotensin-aldosterone system (RAAS) is a critical component of hypertension development. Various elements of RAAS are targets for blood pressure therapy. Prorenin (a precursor of renin) is stored in juxtaglomerular cells (JG cells) within the renal afferent arterioles. Prorenin is enzymatically cleaved to form renin under specific stimuli such as renal hypoperfusion, reduced delivery of sodium and chloride to the distal convoluted tubule (DCT), or increased sympathetic flow through the β-1 adrenergic receptors.<a class="bk_pop" href="#article-160212.r18">[18]</a></p><p>Renin is produced by the liver and initiates the conversion of angiotensinogen into angiotensin I. In the lungs, angiotensin-converting enzyme (ACE) removes 2 amino acids from the C terminal of angiotensin I to form angiotensin II, which regulates blood volume through the AT1 receptor. By inhibiting the binding of angiotensin II to AT1 receptors in the kidneys and adrenal glands, angiotensin receptor blockers impede vasoconstriction and the involvement of aldosterone in the progression of cardiovascular diseases.<a class="bk_pop" href="#article-160212.r19">[19]</a><a class="bk_pop" href="#article-160212.r20">[20]</a> HCTZ is a diuretic agent that acts on the DCTs. Sodium is absorbed in the DCTs and transported to the basolateral aspect of the interstitium through the activity of a sodium-potassium ATPase pump. This process establishes a concentration gradient across the epithelial cells and the DCTs, facilitating water reabsorption. HCTZ hinders sodium and chloride transport by targeting the sodium-chloride symporter, also known as Solute Carrier Family 12 Member 3 (SLC12A3). Through this interruption, HCTZ reduces the concentration difference between the DCT and epithelial cells, reducing water reabsorption and increasing diuresis.<a class="bk_pop" href="#article-160212.r8">[8]</a><a class="bk_pop" href="#article-160212.r21">[21]</a></p><p>ARBs selectively target the AT1 receptor, reducing vasoconstriction and aldosterone secretion induced by angiotensin II. Meanwhile, HCTZ inhibits sodium and water reabsorption in the proximal DCT, promoting diuresis. These mechanisms synergistically reduce blood pressure by mediating vascular tone and fluid volume. This approach optimizes therapeutic efficacy while mitigating the risk of electrolyte imbalances and other adverse effects associated with higher doses of individual agents. A meta-analysis compared ARB-HCTZ therapy to ARB alone in patients with uncontrolled hypertension. Results from 16 RCTs (12,055 participants) indicated that ARB-HCTZ achieved significantly improved systolic and diastolic blood pressures than ARB alone. The combination also increased the likelihood of reaching target blood pressure goals. ARB-HCTZ is associated with rates of adverse events similar to ARB alone.<a class="bk_pop" href="#article-160212.r22">[22]</a></p><p>
|
||
<b>Pharmacokinetics</b>
|
||
</p><p>
|
||
<b>Absorption: </b>Valsartan is rapidly absorbed following oral administration and reaches peak plasma concentration after 1 to 2 hours.<a class="bk_pop" href="#article-160212.r23">[23]</a> Olmesartan is esterified with medoxomil to increase its bioavailability, allowing it to reach peak plasma concentration within 1 to 3 hours.<a class="bk_pop" href="#article-160212.r24">[24]</a> According to FDA-approved product labeling, telmisartan (20 to 160 mg) follows non-linear pharmacokinetics, and its dose-dependent bioavailability ranges from 42% to 58%. The bioavailability of irbesartan is 60% to 80% after a dose. Food intake does not affect its bioavailability. The prodrug candesartan cilexetil is rapidly activated after absorption from the gastrointestinal tract, and its bioavailability is 40% after an oral dose.<a class="bk_pop" href="#article-160212.r25">[25]</a> The bioavailability of losartan is 33%, and concurrent food intake reduces its absorption.<a class="bk_pop" href="#article-160212.r26">[26]</a> The bioavailability of eprosartan after an oral dose of 300 mg is 13%. The bioavailability of HCTZ ranges from 65% to 75%. However, this availability is reduced by 10% when HCTZ is consumed with a meal.<a class="bk_pop" href="#article-160212.r27">[27]</a></p><p>
|
||
<b>Distribution: </b>Valsartan and olmesartan bind strongly to plasma proteins, primarily albumin, which significantly reduces their volume of distribution. The volume of distribution for both drugs is 17 L, implying these medications are not distributed extensively throughout the body. Angiotensin receptor blockers such as telmisartan are highly bound to plasma proteins (>99.5%) regardless of dose amount. Telmisartan's distribution volume is 500 L.<a class="bk_pop" href="#article-160212.r28">[28]</a> Irbesartan is 90% bound to plasma proteins (primarily albumin and α-1-acid glycoprotein), and its volume of distribution ranges from 53 to 93 L. Candesartan is highly bound to plasma proteins and has been shown to cross the blood-brain barrier in animal models; its volume of distribution is 0.13 L/kg. Losartan is 99.7% bound to plasma proteins, giving it poor tissue distribution.<a class="bk_pop" href="#article-160212.r26">[26]</a> Eprosartan at any concentration binds strongly to plasma proteins. HCTZ is 40% to 68% bound to albumin in the serum and extensively distributed throughout the body.<a class="bk_pop" href="#article-160212.r29">[29]</a></p><p>
|
||
<b>Metabolism: </b>Candesartan cilexetil, olmesartan medoxomil, and azilsartan medoxomil are prodrugs requiring metabolic activation in the GIT and liver to form their active counterparts. In contrast, eprosartan, irbesartan, telmisartan, and valsartan are active immediately after administration.<a class="bk_pop" href="#article-160212.r30">[30]</a><b> </b>Valsartan undergoes minimal metabolism.<a class="bk_pop" href="#article-160212.r23">[23]</a> Olmesartan medoxomil is activated into its pharmacologically active form through ester hydrolysis in the gastrointestinal tract; active olmesartan undergoes negligible metabolism.<a class="bk_pop" href="#article-160212.r31">[31]</a> Telmisartan is minimally metabolized through conjugation into the pharmacologically inactive compound acyl-glucuronide without P450 isoenzymes.<a class="bk_pop" href="#article-160212.r28">[28]</a> Irbesartan is primarily metabolized in the liver through glucuronidation and oxidation by CYP2C9. Candesartan cilexetil undergoes ester hydrolysis to form the pharmacologically active candesartan, which is not mainly metabolized in the body. However, <20% of the drug undergoes hepatic metabolism through O-deethylation. The maximum amount of candesartan is excreted unchanged in stools. Losartan undergoes a metabolic transformation into an aldehyde intermediate, producing active metabolites.<a class="bk_pop" href="#article-160212.r26">[26]</a> Eprosartan is not metabolized in the body. HCTZ is also not metabolized in the body and is excreted unchanged in the urine.</p><p>
|
||
<b>Elimination:</b> Valsartan demonstrates bi-exponential decay kinetics, has a half-life of 6 hours, and is excreted almost unchanged in the feces.<a class="bk_pop" href="#article-160212.r23">[23]</a><a class="bk_pop" href="#article-160212.r32">[32]</a> The steady-state concentration of valsartan is achieved after 7 days of twice-daily dosing.<a class="bk_pop" href="#article-160212.r33">[33]</a> Olmesartan has a half-life of 10 to 15 hours, takes 3 to 5 days to attain steady-state concentration (once-daily dosing regimen), and 90% of the dose is excreted in feces, with the remainder excreted in the urine.<a class="bk_pop" href="#article-160212.r24">[24]</a> Telmisartan is widely regarded as the longest-acting ARB, featuring a mean half-life of 24 hours, which conveniently allows for once-daily dosing.<a class="bk_pop" href="#article-160212.r30">[30]</a> This drug demonstrates bi-exponential decay kinetics, has a half-life of 24 hours, and takes 7 daily doses to achieve a steady state.<a class="bk_pop" href="#article-160212.r34">[34]</a> Irbesartan has a half-life of 11 to 15 hours, achieves steady-state concentration in 3 days, and 80% of the dose is excreted in feces, with the remaining excreted in urine. Candesartan reaches its peak concentration in 3 to 4 hours, and its half-life is 9 hours. The active metabolite of losartan has a half-life of 6 to 8 hours. Eprosartan's terminal half-life is 5 to 9 hours. The other ARBs are also eliminated primarily through feces. Hydrochlorothiazide peaks 4 hours after administration and remains effective for approximately 6 to 12 hours; its half-life is 5.6 to 14.8 hours. HCTZ is actively secreted into the proximal tubule by renal organic anion transporters and is eliminated through urine.<a class="bk_pop" href="#article-160212.r29">[29]</a></p></div><div id="article-160212.s4"><h2 id="_article-160212_s4_">Administration</h2><p>
|
||
<b>Available Dosage Forms</b>
|
||
</p><p>The single-pill combination of angiotensin II receptor blockers (ARBs) and hydrochlorothiazide (HCTZ) is available in oral tablet formulations.</p><p>
|
||
<b>Adult Dosage and <b>Strengths</b></b>
|
||
</p><p>
|
||
<b>Valsartan and hydrochlorothiazide</b>
|
||
</p><p>Available doses:</p><ul><li class="half_rhythm"><div>80 mg/12.5 mg</div></li><li class="half_rhythm"><div>160 mg/12.5 mg</div></li><li class="half_rhythm"><div>320 mg/12.5 mg</div></li><li class="half_rhythm"><div>160 mg/25 mg</div></li><li class="half_rhythm"><div>320 mg/25 mg</div></li></ul><p>Initial dose: 160 mg/12.5 mg once daily</p><p>Maximum dose: 320 mg/25 mg once daily</p><p>The dose of the valsartan-HCTZ combination can be titrated 1 to 2 weeks after therapy is initiated, and maximum antihypertensive effects are achieved 2 to 4 weeks after treatment initiation.</p><p>
|
||
<b>Olmesartan and hydrochlorothiazide</b>
|
||
</p><p>Available doses:</p><ul><li class="half_rhythm"><div>20 mg/12.5 mg</div></li><li class="half_rhythm"><div>40 mg/12.5 mg</div></li><li class="half_rhythm"><div>40 mg/25 mg</div></li></ul><p>Initial dose: 20 mg/12.5 mg once daily</p><p>Maximum dose: 40 mg/25 mg once daily</p><p>The dose of olmesartan-HCTZ combination should be titrated every 2 to 4 weeks until blood pressure is controlled.</p><p>
|
||
<b>Telmisartan and hydrochlorothiazide</b>
|
||
</p><p>Available doses:</p><ul><li class="half_rhythm"><div>40 mg/12.5 mg</div></li><li class="half_rhythm"><div>80 mg/12.5 mg</div></li><li class="half_rhythm"><div>80 mg/25 mg</div></li></ul><p>Initial dose: 40 mg/12.5 mg once daily</p><p>Maximum dose: 160 mg/25 mg once daily</p><p>The medication should be started at the lowest possible dose and titrated every 1 to 2 weeks according to the patient's blood pressure.</p><p>
|
||
<b>Irbesartan and hydrochlorothiazide</b>
|
||
</p><p>Available doses:</p><ul><li class="half_rhythm"><div>150 mg/12.5 mg</div></li><li class="half_rhythm"><div>300 mg/12.5 mg</div></li></ul><p>Initial dose: 150 mg/12.5 mg once daily</p><p>Maximum dose: 300 mg/25 mg once daily</p><p>The dosage should be titrated every 1 to 2 weeks. The maximum antihypertensive effect is seen 3 to 4 weeks after treatment is initiated.</p><p>
|
||
<b>Candesartan and hydrochlorothiazide</b>
|
||
</p><p>Available doses:</p><ul><li class="half_rhythm"><div>16 mg/12.5 mg</div></li><li class="half_rhythm"><div>32 mg/12.5 mg</div></li><li class="half_rhythm"><div>32 mg/25 mg</div></li></ul><p>Initial dose: 16 mg/12.5 mg once daily</p><p>Maximum dose: 32 mg/25 mg once daily</p><p>The maximal antihypertensive effect of candesartan and HCTZ is observed 4 weeks after initiating the medication. A patient with uncontrolled blood pressure on 25 mg of HCTZ would only benefit from the combination of 16 mg of candesartan and 12.5 mg of HCTZ. A patient who develops hypokalemia on 25 mg of HCTZ can expect potassium levels to improve after initiating a combination of candesartan and HCTZ.</p><p>
|
||
<b>Losartan and hydrochlorothiazide</b>
|
||
</p><p>Available doses:</p><ul><li class="half_rhythm"><div>50 mg/12.5 mg</div></li><li class="half_rhythm"><div>100 mg/12.5 mg</div></li><li class="half_rhythm"><div>100 mg/25 mg</div></li></ul><p>Initial dose: 50 mg/12.5 mg</p><p>Maximum dose: 100 mg/25 mg daily (ie, 100 mg/25 mg once daily or 50 mg/12.5 mg twice daily)</p><p>The typical starting dose of losartan and HCTZ is 50 mg/12.5 mg. If blood pressure remains uncontrolled after 3 weeks of therapy, the dose can be increased to 100/25 mg once daily.</p><p>
|
||
<b>Eprosartan and hydrochlorothiazide</b>
|
||
</p><p>Available doses:</p><ul><li class="half_rhythm"><div>600 mg/12.5 mg</div></li><li class="half_rhythm"><div>600 mg/25 mg</div></li></ul><p>Initial dose: 600 mg/12.5mg once daily</p><p>Maximum dose: 600 mg/25 mg once daily</p><p>The dose of eprosartan and HCTZ combination can be increased to a maximum of 600 mg/25 mg if blood pressure readings remain high 3 weeks after starting therapy.<a class="bk_pop" href="#article-160212.r22">[22]</a><a class="bk_pop" href="#article-160212.r35">[35]</a></p><p>
|
||
<b>Specific Patient Populations</b>
|
||
</p><p>
|
||
<b>Renal impairment: </b>No dosage changes are required for patients with mild and moderate renal impairment. However, combination ARB-HCTZ medications are contraindicated for patients with end-stage renal disease, as hydrochlorothiazide can induce azotemia in patients with severe renal impairment. According to KDIGO guidelines, hypertension is a significant risk factor for the development and progression of chronic kidney disease (CKD). A diagnosis of CKD is made for patients with an estimated glomerular filtration rate <60 mL/min/1.73 m<sup>2</sup> and a urinary albumin-to-creatinine ratio ≥300 mg/g for 3 months or longer. Among patients with type 1 or type 2 diabetes and CKD, treatment with an ACE inhibitor or ARB reduces the risk of progressing to end-stage renal disease (ESRD). Additionally, antihypertensive therapy mitigates the risk of cardiovascular events.<a class="bk_pop" href="#article-160212.r36">[36]</a> </p><p>
|
||
<b>Hepatic impairment:</b> Minor electrolyte imbalances can precipitate hepatic encephalopathy in patients with cirrhosis; electrolyte levels should be carefully monitored in these patients.<a class="bk_pop" href="#article-160212.r37">[37]</a> Valsartan should be avoided for patients with marked hepatic dysfunction. However, if valsartan must be administered, the daily dose should not exceed 80 mg.<a class="bk_pop" href="#article-160212.r23">[23]</a> Losartan undergoes extensive first-pass metabolism in the liver mediated by the cytochrome P450 system; initial dosing should be half the standard in patients with severe hepatic impairment.<a class="bk_pop" href="#article-160212.r30">[30]</a> ARBs inhibit the renin-angiotensin-aldosterone system (RAAS), reducing vasoconstriction. Compensatory vasoconstriction is critical for maintaining blood pressure in patients with cirrhosis. The American Association for the Study of Liver Diseases (AASLD) guidelines recommend avoiding ARBs for patients with cirrhosis-related ascites due to potential adverse effects on systemic hemodynamics and renal function.<a class="bk_pop" href="#article-160212.r38">[38]</a><a class="bk_pop" href="#article-160212.r39">[39]</a> Thiazide diuretics can cause hypovolemic hyperosmolar hyponatremia in patients with cirrhosis and ascites, especially older patients. The concomitant use of aldosterone antagonists exacerbates this complication.<a class="bk_pop" href="#article-160212.r40">[40]</a></p><p>
|
||
<b>Pregnancy considerations: </b>Medications that target the RAAS can result in fetal renal dysfunction, pulmonary hypoplasia, patent ductus arteriosus, hypocalvaria, and musculoskeletal deformities. HCTZ crosses the placenta and has adverse effects on the fetus, such as hyperbilirubinemia, thrombocytopenia, and oligohydramnios.<a class="bk_pop" href="#article-160212.r41">[41]</a> HCTZ also causes diuresis, which can potentially lead to hypoperfusion of the placenta and subsequent intrauterine growth restriction and fetal distress. According to AHA/ACC guidelines, women with hypertension who are pregnant or planning to become pregnant should switch to methyldopa, nifedipine, or labetalol. Clinicians are advised to avoid prescribing ACE inhibitors, ARBs, or direct renin inhibitors to pregnant women.<a class="bk_pop" href="#article-160212.r8">[8]</a> According to ISH guidelines, renin-angiotensin system (RAS) blockers, including ACE inhibitors, ARBs, and direct renin inhibitors, are contraindicated for pregnant women due to adverse fetal and neonatal outcomes.<a class="bk_pop" href="#article-160212.r10">[10]</a></p><p>
|
||
<b>Breastfeeding considerations: </b>HCTZ is secreted in human milk and is associated with adverse neonatal effects. Women who are nursing must discontinue either the drug or breastfeeding. Intense diuresis induced by HCTZ can reduce breast milk production. Neonates who ingest HCTZ in breast milk may experience acute renal injury, hypokalemia, hyperbilirubinemia, hyponatremia, and hypochloremia. The latter effect is associated with significant mortality among preterm neonates.<a class="bk_pop" href="#article-160212.r42">[42]</a> Intensive diuresis using high doses of diuretics (eg, hydrochlorothiazide 100–150 mg daily) has historically been administered to suppress postpartum lactation. However, no instances of lactation suppression have been reported in patients administered the standard antihypertensive-hydrochlorothiazide doses (25 to 50 mg daily). There is limited information on the effect of ARBs on lactation. However, since all ARBs are highly bound to plasma proteins (>98%) and are poorly absorbed when administered orally, they are thought to be unlikely to affect nursing infants.<a class="bk_pop" href="#article-160212.r43">[43]</a> </p><p>
|
||
<b>Pediatric patients: </b>The safety and efficacy of ARB/HCTZ single-pill combination products have not been established in the pediatric population. However, ARBs have been shown to lower blood pressure in children aged 6 months to 6 years and have a favorable safety profile.<a class="bk_pop" href="#article-160212.r44">[44]</a> Neonates exposed to the ARB-HCTZ combination may require exchange transfusions and dialysis due to renal impairment. The safety of the ARB-HCTZ combination in patients older than 28 days has not been established. </p><p>
|
||
<b>Older patients: </b>No difference in safety, efficacy, or adverse effects profile has been documented in older adults. Diuretic agents may cause orthostatic hypotension in these patients; however, there is no evidence that ARB-HCTZ medications result in this condition in older patients.<a class="bk_pop" href="#article-160212.r45">[45]</a></p></div><div id="article-160212.s5"><h2 id="_article-160212_s5_">Adverse Effects</h2><p>The incidence and severity of adverse reactions were reported lower for patients on ARB-HCTZ combination therapy than for patients taking individual drugs. The incidence of adverse reactions is independent of age, race, or sex. During clinical trials, ARB-HCTZ was discontinued in 2.3% of patients due to adverse effects.</p><p>Severe adverse effects associated with hydrochlorothiazide administration include:</p><ul><li class="half_rhythm"><div>Systemic lupus erythematosus (SLE) flares</div></li><li class="half_rhythm"><div>Hyperuricemia</div></li><li class="half_rhythm"><div>Worsening dyslipidemia</div></li><li class="half_rhythm"><div>Acute angle closure glaucoma</div></li><li class="half_rhythm"><div>Urea level elevations in patients with renal dysfunction</div></li><li class="half_rhythm"><div>Electrolyte imbalances (eg, hypokalemia, hyponatremia, and hypercalcemia)</div></li></ul><p>Hydrochlorothiazide diuretics are also known to cause hyperglycemia, pancreatitis, hyperbilirubinemia, gastroenteritis, aplastic anemia, hemolytic anemia, pulmonary edema, bleeding dyscrasia, headache, vertigo, and blurred vision. The risk of squamous cell carcinoma (non-melanoma skin cancer) was found to be higher for White patients receiving HCTZ compared to the general population.<a class="bk_pop" href="#article-160212.r30">[30]</a><a class="bk_pop" href="#article-160212.r46">[46]</a> There is a significantly higher risk of drug-induced liver injury (DILI) for patients receiving azilsartan compared to valsartan.<a class="bk_pop" href="#article-160212.r47">[47]</a></p><p>The adverse effects associated with ARBs include dizziness, hyperkalemia, sinusitis, angioedema, cough, and enteropathy. The incidence and severity of hypotension increase with the concurrent administration of diuretics such as HCTZ. Providers should avoid prescribing candesartan to patients with hyperuricemia.<a class="bk_pop" href="#article-160212.r48">[48]</a></p><ul><li class="half_rhythm"><div><b>Cough:</b> ARBs increase bradykinin levels, which stimulate the production of prostaglandins that cause bronchial irritation.</div></li><li class="half_rhythm"><div><b>Hypotension:</b> Hypotension is observed more commonly in patients receiving telmisartan. The ONTARGET trial highlighted the impact of hypotension in these patients, leading to the discontinuation of this drug.<a class="bk_pop" href="#article-160212.r49">[49]</a></div></li><li class="half_rhythm"><div><b>Enteropathy:</b> The administration of olmesartan can cause a sprue-like enteropathy.<a class="bk_pop" href="#article-160212.r50">[50]</a> Chronic diarrhea, weight loss, and villous atrophy have been documented. These patients typically test negative for celiac disease, and the symptoms recur if olmesartan is restarted.</div></li><li class="half_rhythm"><div><b>Hyperkalemia:</b> Aldosterone is a significant regulator of potassium excretion. Since ARBs prevent the effects of angiotensin and aldosterone, patients receiving these medications are at an increased risk of hyperkalemia. This adverse effect is more common in patients with chronic kidney disease who are taking potassium-sparing diuretics such as aldactone. To a certain extent, the hypokalemia induced by hydrochlorothiazide is countered by ARB-induced hyperkalemia.<a class="bk_pop" href="#article-160212.r51">[51]</a></div></li></ul><p>
|
||
<b>Drug-Drug Interactions</b>
|
||
</p><p>Concurrent administration of ARB-HCTZ with alcohol, narcotics, and barbiturates can precipitate hypotension. Patients receiving ARB-HCTZ may develop increased responsiveness to lower doses of curare-derived muscle relaxants (eg, rocuronium). Medications that reduce gastrointestinal motility (eg, opioids, atropine) cause increased bioavailability of HCTZ. In contrast, prokinetic agents decrease the bioavailability of the drug combination. Fluconazole inhibits the activation of losartan into its active metabolite, reducing its efficacy. Simultaneous administration of HCTZ and antineoplastic agents can precipitate the latter's toxicity as their renal clearance is reduced. Elevated serum lithium levels have been observed in patients who are also receiving ARB-HCTZ. Co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) can worsen renal function, especially in older and dehydrated patients. When administered simultaneously with drugs such as NSAIDs, ARB-HCTZ can reduce the renal clearance of digoxin, leading to toxicity.<a class="bk_pop" href="#article-160212.r7">[7]</a> According to the product labeling, thiazide diuretics can reduce calcium excretion. Hydrochlorothiazide may also cause minor elevations in blood calcium levels, even in healthy patients. Significant hypercalcemia is suggestive of underlying hyperparathyroidism. Hydrochlorothiazide should be discontinued before assessing parathyroid gland function.<a class="bk_pop" href="#article-160212.r52">[52]</a><a class="bk_pop" href="#article-160212.r7">[7]</a></p></div><div id="article-160212.s6"><h2 id="_article-160212_s6_">Contraindications</h2><p>The combination of ARBs and HCTZ should not be administered to patients with the following conditions:</p><ul><li class="half_rhythm"><div><b>Hypersensitivity to sulfonamide-derived drugs:</b> Individuals with a history of hypersensitivity to any component of the ARB-HCTZ combination, angioedema, or anaphylaxis should not take this medication. These conditions are absolute contraindications to the ARB-HCTZ combination.</div></li></ul><ul><li class="half_rhythm"><div><b>Pregnancy:</b> Both ARBs and HCTZ are known to have teratogenic effects on the developing fetus. Therefore, if a woman becomes pregnant while taking this combination medication, it must be discontinued immediately.</div></li></ul><ul><li class="half_rhythm"><div><b>Receiving aliskiren:</b> The simultaneous administration of aliskiren and ARB-HCTZ significantly increases the risk of hypotension and hyperkalemia.</div></li></ul><ul><li class="half_rhythm"><div><b>Bilateral renal artery stenosis and heart failure with hypotension:</b> Patients with conditions such as bilateral renal artery stenosis and heart failure accompanied by hypotension rely heavily on the RAAS to regulate blood pressure and should not be administered ARBs. In patients with this or similar conditions, ARBs may precipitate renal failure and hyperkalemia.<a class="bk_pop" href="#article-160212.r48">[48]</a></div></li></ul><p>
|
||
<b>Box Warning</b>
|
||
</p><ul><li class="half_rhythm"><div><b>Fetal toxicity:</b> Upon detection of pregnancy, discontinue single pill combinations of ARB-HCTZ promptly. Agents affecting the renin-angiotensin system can result in fetal injury and mortality.<a class="bk_pop" href="#article-160212.r53">[53]</a></div></li></ul><p>
|
||
<b>Warning and Precautions</b>
|
||
</p><ul><li class="half_rhythm"><div>Healthcare providers should remain informed about industry recalls of ARBs, including the past recalls of valsartan, irbesartan, and losartan, due to the presence of contaminants such as NMBA and NDMA. Providers should be aware of the specific batches affected and updates from regulatory agencies like the FDA regarding any new recalls related to these contaminants due to their carcinogenic potential.<a class="bk_pop" href="#article-160212.r54">[54]</a></div></li><li class="half_rhythm"><div>Hydrochlorothiazide administration in kidney transplant recipients is associated with an increased incidence of basal cell carcinoma. This relationship underscores the importance of frequent dermatological monitoring, particularly for patients continuously exposed to sunlight or other ultraviolet sources.<a class="bk_pop" href="#article-160212.r55">[55]</a> Despite previous pharmacovigilance reports suggesting a link, a randomized, placebo-controlled trial involving 30 healthy volunteers found that HCTZ 25 mg daily for 15 days did not increase photosensitivity to UVA or UVB radiation or cause phototoxic or carcinogenic effects. In vitro studies with human keratinocytes also found no adverse effects related to phototoxicity or carcinogenesis due to HCTZ administration combined with UVB exposure.<a class="bk_pop" href="#article-160212.r56">[56]</a> A systematic review and meta-analysis on antihypertensive drugs concluded that diuretics (especially hydrochlorothiazide) are associated with an increased risk of non-melanoma skin cancer (NMSC). However, this risk was predominantly observed during studies that did not adjust for sun exposure or smoking. Cohort studies and studies that corrected these factors did not find a significantly increased risk of NMSC. Furthermore, significant publication bias was identified in some studies. In conclusion, while observational data suggest a link between HCTZ and skin cancer, the evidence from well-controlled studies correcting for confounding factors is less conclusive. Further research and ongoing surveillance is required.<a class="bk_pop" href="#article-160212.r57">[57]</a></div></li></ul></div><div id="article-160212.s7"><h2 id="_article-160212_s7_">Monitoring</h2><p>Serum potassium levels should be monitored in patients with chronic kidney disease who are prescribed ARB-HCTZ. Among the patients who do not have renal dysfunction, potassium is not regularly monitored, as the incidence of new-onset hyperkalemia after ARB administration is 2% and typically rises only 0.2 mmol/L.<a class="bk_pop" href="#article-160212.r58">[58]</a> Hydrochlorothiazide increases potassium excretion and may cause hypokalemia; the hyperkalemia caused by ARBs is balanced by HCTZ-induced hypokalemia.<a class="bk_pop" href="#article-160212.r59">[59]</a> For patients receiving ARB therapy, renal parameters should be monitored routinely. Clinicians should monitor serum glucose levels in patients with diabetes mellitus and prediabetes, as HCTZ can cause hyperglycemia.<a class="bk_pop" href="#article-160212.r17">[17]</a> Patients with a past or family history of hyperuricemia should be monitored for features of an acute flare of gout, as HCTZ causes increased uric acid reabsorption.<a class="bk_pop" href="#article-160212.r60">[60]</a> According to ADA guidelines, serum creatinine elevations (up to 30% above baseline) with ARBs should not be mistaken for acute kidney injury (AKI). Therefore, ARBs should not be discontinued for these minor increases in serum creatinine unless accompanied by volume depletion.<a class="bk_pop" href="#article-160212.r16">[16]</a> According to ESC guidelines, regular patient follow-up is essential during hypertension therapy, as it allows for assessing blood pressure control, evaluating the need for lifestyle and pharmacological treatments, identifying hypertensive-mediated organ damage (HMOD), ascertaining necessary modifications to risk factors, and verifying medication adherence.<a class="bk_pop" href="#article-160212.r61">[61]</a></p></div><div id="article-160212.s8"><h2 id="_article-160212_s8_">Toxicity</h2><p>
|
||
<b>Signs and Symptoms of Overdose</b>
|
||
</p><p>The median lethal dose (LD<sub>50</sub>) of each drug combination depends on the constituent ARB. The literature does not provide toxicity data for each ARB and HCTZ combination. </p><p>An overdose of ARB can cause hypotension, tachycardia, or bradycardia. The LD<sub>50</sub> for each ARB is listed below.</p><ul><li class="half_rhythm"><div>Valsartan: >2 g/kg</div></li><li class="half_rhythm"><div>Olmesartan: >1.5 g/kg</div></li><li class="half_rhythm"><div>Telmisartan: >150 mg/kg</div></li><li class="half_rhythm"><div>Irbesartan: >2000 mg/kg</div></li><li class="half_rhythm"><div>Losartan: >2000 mg/kg</div></li></ul><p>According to animal studies, the LD<sub>50</sub> of HCTZ is >10 g/kg. Hydrochlorothiazide toxicity can cause excessive diuresis, leading to hypotension and electrolyte imbalance.</p><p>
|
||
<b>Management of Overdose</b>
|
||
</p><p>The management of an ARB-HCTZ overdose involves supportive care with intravenous fluids and ensuring electrolyte balance. Terlipressin can be used to treat the patient if the hypotension is not responsive to vasopressors.<a class="bk_pop" href="#article-160212.r62">[62]</a></p></div><div id="article-160212.s9"><h2 id="_article-160212_s9_">Enhancing Healthcare Team Outcomes </h2><p>Adequate management of hypertension is crucial for reducing cardiovascular mortality, as it is one of the major risk factors for cardiovascular diseases. Inadequate control of blood pressure poses a significant public health concern. However, patients can achieve appropriate blood pressure targets through combination therapy, such as the angiotensin receptor blocker-hydrochlorothiazide single-pill combination. This therapy improves blood pressure control and metabolic parameters while reducing other cardiovascular risk factors. Hydrochlorothiazide is available with various angiotensin receptor blockers, including telmisartan, valsartan, olmesartan, candesartan, and losartan. However, caution should be exercised when prescribing the angiotensin receptor blocker and hydrochlorothiazide combination to patients with renal impairments and electrolyte imbalances. Clinicians must rule out absolute contraindications, such as pregnancy, bilateral renal artery stenosis, and concurrent use of aliskiren, before initiating this medication.</p><p>Each healthcare provider should have a clearly defined role in optimizing treatment outcomes. Effective communication among the healthcare team members is crucial to ensuring appropriate patient care. During one prospective study, pharmacist-managed hypertension care in collaboration with physicians led to an average systolic blood pressure (SBP) reduction of 10.83 mm Hg. A greater proportion of patients in the pharmacist-managed group achieved their blood pressure goal (<130/80 mm Hg) compared to those managed solely by physicians (56.5% vs. 20.8%, P = 0.012). These findings underscore the benefit of pharmacist involvement in improving hypertension management outcomes in ambulatory care settings.<a class="bk_pop" href="#article-160212.r63">[63]</a> Evidence-based practice should guide the selection of antihypertensive therapy, and healthcare providers should thoroughly explain the potential adverse effects and benefits of the angiotensin receptor blocker and hydrochlorothiazide combination to the patient and any caregivers. By promoting coordination and communication among healthcare team members, errors are minimized, and patient outcomes are improved. Cardiologists and nephrologists should be consulted regarding secondary causes of hypertension and end-organ damage. Emergency medicine physicians should be consulted for rapid stabilization of patients who have overdosed. An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, and nurses significantly reduces potential adverse effects, improves the disease course, and improves patient outcomes related to angiotensin receptor blocker and hydrochlorothiazide therapy.</p></div><div id="article-160212.s10"><h2 id="_article-160212_s10_">Review Questions</h2><ul><li class="half_rhythm"><div>
|
||
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=160212&utm_source=pubmed&utm_campaign=reviews&utm_content=160212" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="https://www.statpearls.com/articlelibrary/commentarticle/160212/?utm_source=pubmed&utm_campaign=comments&utm_content=160212" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Comment on this article.</a>
|
||
</div></li></ul></div><div id="article-160212.s11"><h2 id="_article-160212_s11_">References</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="article-160212.r1">Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension Prevalence Among Adults Aged 18 and Over: United States, 2017-2018. <span><span class="ref-journal">NCHS Data Brief. </span>2020 Apr;(364):1-8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32487290" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32487290</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="article-160212.r2">Dai H, Bragazzi NL, Younis A, Zhong W, Liu X, Wu J, Grossman E. Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease From 1990 to 2017. <span><span class="ref-journal">Hypertension. </span>2021 Apr;<span class="ref-vol">77</span>(4):1223-1233.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33583201" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33583201</span></a>]</div></dd><dt>3.</dt><dd><div class="bk_ref" id="article-160212.r3">Mirabito Colafella KM, Bovée DM, Danser AHJ. The renin-angiotensin-aldosterone system and its therapeutic targets. <span><span class="ref-journal">Exp Eye Res. </span>2019 Sep;<span class="ref-vol">186</span>:107680.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31129252" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31129252</span></a>]</div></dd><dt>4.</dt><dd><div class="bk_ref" id="article-160212.r4">Presta V, Figliuzzi I, Citoni B, Gallo G, Battistoni A, Tocci G, Volpe M. ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. <span><span class="ref-journal">High Blood Press Cardiovasc Prev. </span>2021 May;<span class="ref-vol">28</span>(3):255-262.</span> [<a href="/pmc/articles/PMC7953181/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7953181</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33710599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33710599</span></a>]</div></dd><dt>5.</dt><dd><div class="bk_ref" id="article-160212.r5">Lee W, Kang J, Park JB, Seo WW, Lee SY, Lim WH, Jeon KH, Hwang IC, Kim HL. Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real-world database: A retrospective cohort study. <span><span class="ref-journal">Health Sci Rep. </span>2023 Feb;<span class="ref-vol">6</span>(2):e1056.</span> [<a href="/pmc/articles/PMC9889622/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9889622</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36741853" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36741853</span></a>]</div></dd><dt>6.</dt><dd><div class="bk_ref" id="article-160212.r6">Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB., American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <span><span class="ref-journal">J Am Soc Hypertens. </span>2015 Jun;<span class="ref-vol">9</span>(6):453-98.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25840695" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25840695</span></a>]</div></dd><dt>7.</dt><dd><div class="bk_ref" id="article-160212.r7">Teles F, Peçanha de Miranda Coelho JA, Albino RM, Verçosa Pacheco FC, Rodrigues de Oliveira E, Silveira MAD, Diógenes M Feitosa A, Bezerra R. Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: a systematic review and meta-analysis. <span><span class="ref-journal">Ren Fail. </span>2023 Dec;<span class="ref-vol">45</span>(1):2163903.</span> [<a href="/pmc/articles/PMC9848247/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9848247</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36637019" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36637019</span></a>]</div></dd><dt>8.</dt><dd><div class="bk_ref" id="article-160212.r8">Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <span><span class="ref-journal">Hypertension. </span>2018 Jun;<span class="ref-vol">71</span>(6):e13-e115.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29133356</span></a>]</div></dd><dt>9.</dt><dd><div class="bk_ref" id="article-160212.r9">King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress AP. Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. <span><span class="ref-journal">Hypertension. </span>2023 Aug;<span class="ref-vol">80</span>(8):1749-1758.</span> [<a href="/pmc/articles/PMC10483993/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10483993</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37288570" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37288570</span></a>]</div></dd><dt>10.</dt><dd><div class="bk_ref" id="article-160212.r10">Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. <span><span class="ref-journal">Hypertension. </span>2020 Jun;<span class="ref-vol">75</span>(6):1334-1357.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32370572" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32370572</span></a>]</div></dd><dt>11.</dt><dd><div class="bk_ref" id="article-160212.r11">Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). <span><span class="ref-journal">J Hypertens. </span>2023 Dec 01;<span class="ref-vol">41</span>(12):1874-2071.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37345492" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37345492</span></a>]</div></dd><dt>12.</dt><dd><div class="bk_ref" id="article-160212.r12">Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, Pratt N, Reich CG, Madigan D, You SC, Ryan PB, Hripcsak G. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. <span><span class="ref-journal">Hypertension. </span>2021 Sep;<span class="ref-vol">78</span>(3):591-603.</span> [<a href="/pmc/articles/PMC8363588/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8363588</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34304580" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34304580</span></a>]</div></dd><dt>13.</dt><dd><div class="bk_ref" id="article-160212.r13">Kjeldsen SE, Lyle PA, Kizer JR, Oparil S, Høieggen A, Os I. Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. <span><span class="ref-journal">Vasc Health Risk Manag. </span>2007;<span class="ref-vol">3</span>(3):299-305.</span> [<a href="/pmc/articles/PMC2293966/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2293966</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17703637" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17703637</span></a>]</div></dd><dt>14.</dt><dd><div class="bk_ref" id="article-160212.r14">Helmer A, Slater N, Smithgall S. A Review of ACE Inhibitors and ARBs in Black Patients With Hypertension. <span><span class="ref-journal">Ann Pharmacother. </span>2018 Nov;<span class="ref-vol">52</span>(11):1143-1151.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29808707" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29808707</span></a>]</div></dd><dt>15.</dt><dd><div class="bk_ref" id="article-160212.r15">Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <span><span class="ref-journal">Circulation. </span>2022 May 03;<span class="ref-vol">145</span>(18):e895-e1032.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35363499" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35363499</span></a>]</div></dd><dt>16.</dt><dd><div class="bk_ref" id="article-160212.r16">American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. <span><span class="ref-journal">Diabetes Care. </span>2022 Jan 01;<span class="ref-vol">45</span>(Suppl 1):S175-S184.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34964873" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34964873</span></a>]</div></dd><dt>17.</dt><dd><div class="bk_ref" id="article-160212.r17">Zhang X, Zhao Q. Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. <span><span class="ref-journal">J Clin Hypertens (Greenwich). </span>2016 Apr;<span class="ref-vol">18</span>(4):342-51.</span> [<a href="/pmc/articles/PMC8031670/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8031670</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26395424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26395424</span></a>]</div></dd><dt>18.</dt><dd><div class="bk_ref" id="article-160212.r18"><span class="ref-journal">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</span> National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 13, 2017. Angiotensin II Receptor Antagonists. [<a href="https://pubmed.ncbi.nlm.nih.gov/31643954" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31643954</span></a>]</div></dd><dt>19.</dt><dd><div class="bk_ref" id="article-160212.r19">Paulis L, Foulquier S, Namsolleck P, Recarti C, Steckelings UM, Unger T. Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders. <span><span class="ref-journal">Drugs. </span>2016 Jan;<span class="ref-vol">76</span>(1):1-12.</span> [<a href="/pmc/articles/PMC4700059/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4700059</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26631237" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26631237</span></a>]</div></dd><dt>20.</dt><dd><div class="bk_ref" id="article-160212.r20">Almutlaq M, Alamro AA, Alroqi F, Barhoumi T. Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology. <span><span class="ref-journal">CJC Open. </span>2021 Aug;<span class="ref-vol">3</span>(8):1060-1074.</span> [<a href="/pmc/articles/PMC8046706/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8046706</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33875979" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33875979</span></a>]</div></dd><dt>21.</dt><dd><div class="bk_ref" id="article-160212.r21">Ernst ME, Fravel MA. Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide. <span><span class="ref-journal">Am J Hypertens. </span>2022 Jul 01;<span class="ref-vol">35</span>(7):573-586.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35404993" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35404993</span></a>]</div></dd><dt>22.</dt><dd><div class="bk_ref" id="article-160212.r22">Ma L, Zheng K, Yan J, Cheng W. Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis. <span><span class="ref-journal">Int J Hypertens. </span>2021;<span class="ref-vol">2021</span>:6670183.</span> [<a href="/pmc/articles/PMC8096582/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8096582</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33996152" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33996152</span></a>]</div></dd><dt>23.</dt><dd><div class="bk_ref" id="article-160212.r23">Thürmann PA. Valsartan: a novel angiotensin type 1 receptor antagonist. <span><span class="ref-journal">Expert Opin Pharmacother. </span>2000 Jan;<span class="ref-vol">1</span>(2):337-50.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11249553" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11249553</span></a>]</div></dd><dt>24.</dt><dd><div class="bk_ref" id="article-160212.r24">Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. <span><span class="ref-journal">J Hum Hypertens. </span>2002 May;<span class="ref-vol">16 Suppl 2</span>:S13-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11967728" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11967728</span></a>]</div></dd><dt>25.</dt><dd><div class="bk_ref" id="article-160212.r25">Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. <span><span class="ref-journal">Clin Pharmacokinet. </span>2002;<span class="ref-vol">41</span>(1):7-17.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11825094" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11825094</span></a>]</div></dd><dt>26.</dt><dd><div class="bk_ref" id="article-160212.r26">Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. <span><span class="ref-journal">Clin Pharmacokinet. </span>2005;<span class="ref-vol">44</span>(8):797-814.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16029066" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16029066</span></a>]</div></dd><dt>27.</dt><dd><div class="bk_ref" id="article-160212.r27">Castilla-Ojo N, Turkson-Ocran RA, Conlin PR, Appel LJ, Miller ER, Juraschek SP. Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial. <span><span class="ref-journal">J Clin Hypertens (Greenwich). </span>2023 Oct;<span class="ref-vol">25</span>(10):915-922.</span> [<a href="/pmc/articles/PMC10560966/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10560966</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37695134" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37695134</span></a>]</div></dd><dt>28.</dt><dd><div class="bk_ref" id="article-160212.r28">Balakumar P, Bishnoi HK, Mahadevan N. Telmisartan in the management of diabetic nephropathy: a contemporary view. <span><span class="ref-journal">Curr Diabetes Rev. </span>2012 May;<span class="ref-vol">8</span>(3):183-90.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22429010" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22429010</span></a>]</div></dd><dt>29.</dt><dd><div class="bk_ref" id="article-160212.r29">Commander SJ, Wu H, Boakye-Agyeman F, Melloni C, Hornik CD, Zimmerman K, Al-Uzri A, Mendley SR, Harper B, Cohen-Wolkowiez M, Hornik CP., Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation. <span><span class="ref-journal">J Clin Pharmacol. </span>2021 Mar;<span class="ref-vol">61</span>(3):368-377.</span> [<a href="/pmc/articles/PMC8232568/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8232568</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33029806" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33029806</span></a>]</div></dd><dt>30.</dt><dd><div class="bk_ref" id="article-160212.r30">Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. <span><span class="ref-journal">Drug Saf. </span>2015 Jan;<span class="ref-vol">38</span>(1):33-54.</span> [<a href="/pmc/articles/PMC4303500/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4303500</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25416320" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25416320</span></a>]</div></dd><dt>31.</dt><dd><div class="bk_ref" id="article-160212.r31">Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. <span><span class="ref-journal">Vasc Health Risk Manag. </span>2006;<span class="ref-vol">2</span>(4):327-40.</span> [<a href="/pmc/articles/PMC1994016/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1994016</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17323586" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17323586</span></a>]</div></dd><dt>32.</dt><dd><div class="bk_ref" id="article-160212.r32">Fogari R, Zoppi A. A drug safety evaluation of valsartan. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2011 Mar;<span class="ref-vol">10</span>(2):295-303.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21142805" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21142805</span></a>]</div></dd><dt>33.</dt><dd><div class="bk_ref" id="article-160212.r33">Prasad PP, Yeh CM, Gurrieri P, Glazer R, McLeod J. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. <span><span class="ref-journal">J Cardiovasc Pharmacol. </span>2002 Nov;<span class="ref-vol">40</span>(5):801-7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12409989" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12409989</span></a>]</div></dd><dt>34.</dt><dd><div class="bk_ref" id="article-160212.r34">Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. <span><span class="ref-journal">J Int Med Res. </span>2000 Jul-Aug;<span class="ref-vol">28</span>(4):149-67.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11014323" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11014323</span></a>]</div></dd><dt>35.</dt><dd><div class="bk_ref" id="article-160212.r35">Bönner G., Multicentre Study Group. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. <span><span class="ref-journal">Blood Press Suppl. </span>2008 Dec;<span class="ref-vol">2</span>:22-30.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19203019" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19203019</span></a>]</div></dd><dt>36.</dt><dd><div class="bk_ref" id="article-160212.r36">Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <span><span class="ref-journal">Kidney Int. </span>2022 Nov;<span class="ref-vol">102</span>(5S):S1-S127.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36272764" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36272764</span></a>]</div></dd><dt>37.</dt><dd><div class="bk_ref" id="article-160212.r37">Dézsi CA. The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? <span><span class="ref-journal">Am J Cardiovasc Drugs. </span>2016 Aug;<span class="ref-vol">16</span>(4):255-266.</span> [<a href="/pmc/articles/PMC4947116/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4947116</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26940560" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26940560</span></a>]</div></dd><dt>38.</dt><dd><div class="bk_ref" id="article-160212.r38">Runyon BA., AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <span><span class="ref-journal">Hepatology. </span>2013 Apr;<span class="ref-vol">57</span>(4):1651-3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23463403" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23463403</span></a>]</div></dd><dt>39.</dt><dd><div class="bk_ref" id="article-160212.r39">Elhence H, Dodge JL, Lee BP. Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2024 Feb;<span class="ref-vol">22</span>(2):315-323.e17.</span> [<a href="/pmc/articles/PMC11232660/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11232660</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37495200" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37495200</span></a>]</div></dd><dt>40.</dt><dd><div class="bk_ref" id="article-160212.r40">Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites. <span><span class="ref-journal">World J Gastroenterol. </span>2019 Jul 28;<span class="ref-vol">25</span>(28):3738-3752.</span> [<a href="/pmc/articles/PMC6676543/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6676543</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31391769" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31391769</span></a>]</div></dd><dt>41.</dt><dd><div class="bk_ref" id="article-160212.r41">Hoeltzenbein M, Tissen-Diabaté T, Fietz AK, Zinke S, Kayser A, Meister R, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study. <span><span class="ref-journal">Clin Res Cardiol. </span>2018 Aug;<span class="ref-vol">107</span>(8):679-687.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29574489" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29574489</span></a>]</div></dd><dt>42.</dt><dd><div class="bk_ref" id="article-160212.r42">Kalikkot Thekkeveedu R, Ramarao S, Dankhara N, Alur P. Hypochloremia Secondary to Diuretics in Preterm Infants: Should Clinicians Pay Close Attention? <span><span class="ref-journal">Glob Pediatr Health. </span>2021;<span class="ref-vol">8</span>:2333794X21991014.</span> [<a href="/pmc/articles/PMC7868482/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7868482</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33614850" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33614850</span></a>]</div></dd><dt>43.</dt><dd><div class="bk_ref" id="article-160212.r43">Anderson PO. Treating Hypertension During Breastfeeding. <span><span class="ref-journal">Breastfeed Med. </span>2018 Mar;<span class="ref-vol">13</span>(2):95-96.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29369692" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29369692</span></a>]</div></dd><dt>44.</dt><dd><div class="bk_ref" id="article-160212.r44">Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, Santoro EP, McCrary Sisk C, Blaustein RO. A randomized, open-label, dose-response study of losartan in hypertensive children. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2014 Aug 07;<span class="ref-vol">9</span>(8):1441-8.</span> [<a href="/pmc/articles/PMC4123403/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4123403</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24875194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24875194</span></a>]</div></dd><dt>45.</dt><dd><div class="bk_ref" id="article-160212.r45">Kjeldsen SE, Schumacher H, Neldam S, Guthrie RM. Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. <span><span class="ref-journal">J Clin Hypertens (Greenwich). </span>2013 Jun;<span class="ref-vol">15</span>(6):380-8.</span> [<a href="/pmc/articles/PMC8033787/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8033787</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23730986" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23730986</span></a>]</div></dd><dt>46.</dt><dd><div class="bk_ref" id="article-160212.r46">Edwards C, Hundemer GL, Petrcich W, Canney M, Knoll G, Burns K, Bugeja A, Sood MM. Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. <span><span class="ref-journal">JAMA Netw Open. </span>2021 Sep 01;<span class="ref-vol">4</span>(9):e2123365.</span> [<a href="/pmc/articles/PMC8444030/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8444030</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34524440" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34524440</span></a>]</div></dd><dt>47.</dt><dd><div class="bk_ref" id="article-160212.r47">Kim H, Son N, Jeong D, Yoo M, Choi IY, Choi W, Chung YW, Ko SW, Byun S, Im S, Sim DW, Seo J, Kang MG, Lee JK, Seo YG, An HJ, Kim Y, Chae S, Jun DW, Chang DJ, Kim SG, Yi S, Yang HJ, Lee I, Park HJ, Lee JH, Kim B, Lee EE. Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea. <span><span class="ref-journal">Drug Saf. </span>2024 Jul;<span class="ref-vol">47</span>(7):673-686.</span> [<a href="/pmc/articles/PMC11182788/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11182788</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38512445" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38512445</span></a>]</div></dd><dt>48.</dt><dd><div class="bk_ref" id="article-160212.r48">Hill RD, Vaidya PN. <span class="ref-journal">StatPearls [Internet].</span> StatPearls Publishing; Treasure Island (FL): Mar 27, 2023. Angiotensin II Receptor Blockers (ARB) [<a href="https://pubmed.ncbi.nlm.nih.gov/30725712" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30725712</span></a>]</div></dd><dt>49.</dt><dd><div class="bk_ref" id="article-160212.r49">Berlaimont V, Billiouw JM, Brohet C, Dupont AG, Gazagnes MD, Heller F, Krzesinski JM, Missault L, Persu A, Piérard L, Rottiers R, Vanhooren G, Van Mieghem W, Vervaet P, Herman AG. Lessons from ONTARGET. <span><span class="ref-journal">Acta Clin Belg. </span>2008 May-Jun;<span class="ref-vol">63</span>(3):142-51.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18714845" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18714845</span></a>]</div></dd><dt>50.</dt><dd><div class="bk_ref" id="article-160212.r50">Bashari DR. Severe Sprue-Like Enteropathy and Colitis due to Olmesartan: Lessons Learned From a Rare Entity. <span><span class="ref-journal">Gastroenterology Res. </span>2020 Aug;<span class="ref-vol">13</span>(4):150-154.</span> [<a href="/pmc/articles/PMC7433370/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7433370</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32864026" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32864026</span></a>]</div></dd><dt>51.</dt><dd><div class="bk_ref" id="article-160212.r51">Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. <span><span class="ref-journal">Cleve Clin J Med. </span>2019 Sep;<span class="ref-vol">86</span>(9):601-607.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31498767" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31498767</span></a>]</div></dd><dt>52.</dt><dd><div class="bk_ref" id="article-160212.r52">Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ, Wermers RA. Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2016 Mar;<span class="ref-vol">101</span>(3):1166-73.</span> [<a href="/pmc/articles/PMC4803175/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4803175</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26751196" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26751196</span></a>]</div></dd><dt>53.</dt><dd><div class="bk_ref" id="article-160212.r53">Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis. <span><span class="ref-journal">Pharmacol Res Perspect. </span>2020 Oct;<span class="ref-vol">8</span>(5):e00644.</span> [<a href="/pmc/articles/PMC7438312/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7438312</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32815286" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32815286</span></a>]</div></dd><dt>54.</dt><dd><div class="bk_ref" id="article-160212.r54">Gillette M, Taylor A, Butulija D, Kadiyala H, Jneid H. Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare. <span><span class="ref-journal">Cardiovasc Drugs Ther. </span>2020 Aug;<span class="ref-vol">34</span>(4):579-584.</span> [<a href="/pmc/articles/PMC7171054/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7171054</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32318933" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32318933</span></a>]</div></dd><dt>55.</dt><dd><div class="bk_ref" id="article-160212.r55">Rahamimov R, Telem S, Davidovichi B, Bielopolski D, Steinmetz T, Nesher E, Lichtenberg S, Rozen-Zvi B. The association between hydrochlorothiazide use and non-melanoma skin cancer in kidney transplant recipients. <span><span class="ref-journal">Clin Kidney J. </span>2024 May;<span class="ref-vol">17</span>(5):sfae126.</span> [<a href="/pmc/articles/PMC11134297/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11134297</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38812910" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38812910</span></a>]</div></dd><dt>56.</dt><dd><div class="bk_ref" id="article-160212.r56">Götzinger F, Hohl M, Lauder L, Millenaar D, Kunz M, Meyer MR, Ukena C, Lerche CM, Philipsen PA, Reichrath J, Böhm M, Mahfoud F. A randomized, placebo-controlled, trial to assess the photosensitizing, phototoxic and carcinogenic potential of hydrochlorothiazide in healthy volunteers. <span><span class="ref-journal">J Hypertens. </span>2023 Nov 01;<span class="ref-vol">41</span>(11):1853-1862.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37702559" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37702559</span></a>]</div></dd><dt>57.</dt><dd><div class="bk_ref" id="article-160212.r57">Heisel AGU, Vuurboom MD, Daams JG, de Rie MA, Vogt L, van den Born BH, Olde Engberink RHG. The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis. <span><span class="ref-journal">Vascul Pharmacol. </span>2023 Jun;<span class="ref-vol">150</span>:107173.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37084802" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37084802</span></a>]</div></dd><dt>58.</dt><dd><div class="bk_ref" id="article-160212.r58">Desai A. Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit. <span><span class="ref-journal">Circulation. </span>2008 Oct 14;<span class="ref-vol">118</span>(16):1609-11.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18852376" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18852376</span></a>]</div></dd><dt>59.</dt><dd><div class="bk_ref" id="article-160212.r59">Palmer BF. Metabolic complications associated with use of diuretics. <span><span class="ref-journal">Semin Nephrol. </span>2011 Nov;<span class="ref-vol">31</span>(6):542-52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22099511" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22099511</span></a>]</div></dd><dt>60.</dt><dd><div class="bk_ref" id="article-160212.r60">Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. <span><span class="ref-journal">BMJ. </span>2012 Jan 12;<span class="ref-vol">344</span>:d8190.</span> [<a href="/pmc/articles/PMC3257215/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3257215</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22240117" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22240117</span></a>]</div></dd><dt>61.</dt><dd><div class="bk_ref" id="article-160212.r61">Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, de Pinho RM, Albini FL, Boivin JM, Doumas M, Nemcsik J, Rodilla E, Agabiti-Rosei E, Algharably EAE, Agnelli G, Benetos A, Hitij JB, Cífková R, Cornelissen V, Danser AHJ, Delles C, Huelgas RG, Járai Z, Palatini P, Pathak A, Persu A, Polonia J, Sarafidis P, Stergiou G, Thomopoulos C, Wanner C, Weber T, Williams B, Kjeldsen SE, Mancia G. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. <span><span class="ref-journal">Eur J Intern Med. </span>2024 Aug;<span class="ref-vol">126</span>:1-15.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/38914505" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38914505</span></a>]</div></dd><dt>62.</dt><dd><div class="bk_ref" id="article-160212.r62">Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, Galli E. Telmisartan: just an antihypertensive agent? A literature review. <span><span class="ref-journal">Expert Opin Pharmacother. </span>2011 Dec;<span class="ref-vol">12</span>(17):2719-35.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22077832" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22077832</span></a>]</div></dd><dt>63.</dt><dd><div class="bk_ref" id="article-160212.r63">Chonko K, Axtell S, Mayzel B. Pharmacist Hypertension Management Quality Review at an Ambulatory Care Clinic. <span><span class="ref-journal">J Pharm Technol. </span>2022 Feb;<span class="ref-vol">38</span>(1):31-38.</span> [<a href="/pmc/articles/PMC8820044/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8820044</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35141725" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35141725</span></a>]</div></dd></dl></div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_top_margin">
|
||
<b>Disclosure: </b> Sheeba Sagar declares no relevant financial relationships with ineligible companies.</p></div></dd><dt></dt><dd><div><p class="no_top_margin">
|
||
<b>Disclosure: </b>Preeti Patel declares no relevant financial relationships with ineligible companies.</p></div></dd></dl></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 2025, StatPearls Publishing LLC.<p class="small">
|
||
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
|
||
(<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">
|
||
http://creativecommons.org/licenses/by-nc-nd/4.0/
|
||
</a>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
|
||
</p></div><div class="small"><span class="label">Bookshelf ID: NBK606100</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39163455" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">39163455</a></span></div></div></div>
|
||
|
||
</div>
|
||
|
||
<!-- Custom content below content -->
|
||
<div class="col4">
|
||
|
||
</div>
|
||
|
||
|
||
<!-- Book content -->
|
||
|
||
<!-- Custom contetnt below bottom nav -->
|
||
<div class="col5">
|
||
|
||
</div>
|
||
</div>
|
||
|
||
<div id="rightcolumn" class="four_col col last">
|
||
<!-- Custom content above discovery portlets -->
|
||
<div class="col6">
|
||
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK606100&db=books">Share</a></div>
|
||
|
||
</div>
|
||
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK606100/?report=reader">PubReader</a></li><li><a href="/books/NBK606100/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK606100" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK606100" style="display:none" title="Cite this Page"><div class="bk_tt">Sagar S, Patel P. Angiotensin Receptor Blockers and HCTZ Combination Drugs. [Updated 2024 Aug 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. <span class="bk_cite_avail"></span></div></div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#article-160212.s1" ref="log$=inpage&link_id=inpage">Continuing Education Activity</a></li><li><a href="#article-160212.s2" ref="log$=inpage&link_id=inpage">Indications</a></li><li><a href="#article-160212.s3" ref="log$=inpage&link_id=inpage">Mechanism of Action</a></li><li><a href="#article-160212.s4" ref="log$=inpage&link_id=inpage">Administration</a></li><li><a href="#article-160212.s5" ref="log$=inpage&link_id=inpage">Adverse Effects</a></li><li><a href="#article-160212.s6" ref="log$=inpage&link_id=inpage">Contraindications</a></li><li><a href="#article-160212.s7" ref="log$=inpage&link_id=inpage">Monitoring</a></li><li><a href="#article-160212.s8" ref="log$=inpage&link_id=inpage">Toxicity</a></li><li><a href="#article-160212.s9" ref="log$=inpage&link_id=inpage">Enhancing Healthcare Team Outcomes </a></li><li><a href="#article-160212.s10" ref="log$=inpage&link_id=inpage">Review Questions</a></li><li><a href="#article-160212.s11" ref="log$=inpage&link_id=inpage">References</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/3d/12/" ref="pagearea=source-links&targetsite=external&targetcat=link&targettype=uri">Bulk download StatPearls data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=5656154" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=5656154" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/39455534" ref="ordinalpos=1&linkpos=1&log$=relatedarticles&logdbfrom=pubmed">ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.</a><span class="source">[Cardiol Ther. 2024]</span><div class="brieflinkpop offscreen_noflow">ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sobhy M, Eletriby A, Ragy H, Kandil H, Saleh MA, Farag N, Guindy R, Bendary A, Nayel AME, Shawky A, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cardiol Ther. 2024 Dec; 13(4):707-736. Epub 2024 Oct 25.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/39163066" ref="ordinalpos=1&linkpos=2&log$=relatedarticles&logdbfrom=pubmed">Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians.</a><span class="source">[J Assoc Physicians India. 2024]</span><div class="brieflinkpop offscreen_noflow">Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wander GS, Panda JK, Pal J, Mathur G, Sahay R, Tiwaskar M, Chatterjee N, Chakrabarty S, Singh DP, Murthy LS, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Assoc Physicians India. 2024 Aug; 72(8):e1-e25. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/34022072" ref="ordinalpos=1&linkpos=3&log$=relatedarticles&logdbfrom=pubmed">Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.</a><span class="source">[Cochrane Database Syst Rev. 2021]</span><div class="brieflinkpop offscreen_noflow">Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Martin N, Manoharan K, Davies C, Lumbers RT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2021 May 22; 5(5):CD012721. Epub 2021 May 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301510" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> FBN1-Related Marfan Syndrome.</a><span class="source">[GeneReviews(®). 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> FBN1-Related Marfan Syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dietz H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews(®). 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29952095" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.</a><span class="source">[Cochrane Database Syst Rev. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2018 Jun 28; 6(6):CD012721. Epub 2018 Jun 28.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=39163455" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=39163455" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c80b37d5edb449bf6714e6">Angiotensin Receptor Blockers and HCTZ Combination Drugs - StatPearls</a><div class="ralinkpop offscreen_noflow">Angiotensin Receptor Blockers and HCTZ Combination Drugs - StatPearls<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c80b35d5edb449bf6704f6">Anophthalmic Socket - StatPearls</a><div class="ralinkpop offscreen_noflow">Anophthalmic Socket - StatPearls<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=67c80b336d1ec11b6f830587">Anticoagulant Therapy In Pregnancy - StatPearls</a><div class="ralinkpop offscreen_noflow">Anticoagulant Therapy In Pregnancy - StatPearls<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=4" href="/portal/utils/pageresolver.fcgi?recordid=67c80b32feee5b00ac23e0c2">Batten Disease (Juvenile Neuronal Ceroid Lipofuscinosis) - StatPearls</a><div class="ralinkpop offscreen_noflow">Batten Disease (Juvenile Neuronal Ceroid Lipofuscinosis) - StatPearls<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=5" href="/portal/utils/pageresolver.fcgi?recordid=67c80b30b70fbb196028acd9">Quality of Well-being Scale - StatPearls</a><div class="ralinkpop offscreen_noflow">Quality of Well-being Scale - StatPearls<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
||
|
||
<!-- Custom content below discovery portlets -->
|
||
<div class="col7">
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Custom content after all -->
|
||
<div class="col8">
|
||
|
||
</div>
|
||
<div class="col9">
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
||
<script type="text/javascript">
|
||
(function($){
|
||
$('.skiplink').each(function(i, item){
|
||
var href = $($(item).attr('href'));
|
||
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
||
$(item).on('click', function(event){
|
||
event.preventDefault();
|
||
$.scrollTo(href, 0, {
|
||
onAfter: function(){
|
||
href.focus();
|
||
}
|
||
});
|
||
});
|
||
});
|
||
})(jQuery);
|
||
</script>
|
||
</div>
|
||
<div class="bottom">
|
||
<script type="text/javascript">
|
||
var PBooksSearchTermData = {
|
||
highlighter: "bold",
|
||
dateTime: "03/05/2025 03:12:13",
|
||
terms: [
|
||
'2010'
|
||
]
|
||
};
|
||
</script>
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<div class="footer" id="footer">
|
||
<section class="icon-section">
|
||
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
||
<div class="grid-container container">
|
||
<div class="icon-section_container">
|
||
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<defs>
|
||
<style>
|
||
.cls-11 {
|
||
fill: #737373;
|
||
}
|
||
</style>
|
||
</defs>
|
||
<title>Twitter</title>
|
||
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<title>Facebook</title>
|
||
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<title>LinkedIn</title>
|
||
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<defs>
|
||
<style>
|
||
.cls-11,
|
||
.cls-12 {
|
||
fill: #737373;
|
||
}
|
||
|
||
.cls-11 {
|
||
fill-rule: evenodd;
|
||
}
|
||
</style>
|
||
</defs>
|
||
<title>GitHub</title>
|
||
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
||
</path>
|
||
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
||
</path>
|
||
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
||
</path>
|
||
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
||
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
||
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
||
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
||
<title>NCBI Insights Blog</title>
|
||
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
||
</svg>
|
||
</a>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<section class="container-fluid bg-primary">
|
||
<div class="container pt-5">
|
||
<div class="row mt-3">
|
||
<div class="col-lg-3 col-12">
|
||
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
||
<ul class="list-inline social_media">
|
||
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<style type="text/css">
|
||
.st20 {
|
||
fill: #FFFFFF;
|
||
}
|
||
|
||
.st30 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
</style>
|
||
<title>Twitter</title>
|
||
<g>
|
||
<g>
|
||
<g>
|
||
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
||
</g>
|
||
</g>
|
||
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
||
</g>
|
||
</svg></a></li>
|
||
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
||
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<style type="text/css">
|
||
.st10 {
|
||
fill: #FFFFFF;
|
||
}
|
||
|
||
.st110 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
</style>
|
||
<title>Facebook</title>
|
||
<g>
|
||
<g>
|
||
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
||
</g>
|
||
</g>
|
||
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
||
</svg>
|
||
</a></li>
|
||
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<title>Youtube</title>
|
||
<style type="text/css">
|
||
.st4 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
|
||
.st5 {
|
||
fill: #FFFFFF;
|
||
}
|
||
</style>
|
||
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
||
<g transform="translate(0,-952.36218)">
|
||
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
||
</g>
|
||
</svg></a></li>
|
||
</ul>
|
||
</div>
|
||
<div class="col-lg-3 col-12">
|
||
<p class="address_footer text-white">National Library of Medicine<br />
|
||
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
||
Bethesda, MD 20894</a></p>
|
||
</div>
|
||
<div class="col-lg-3 col-12 centered-lg">
|
||
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
||
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
||
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
||
</div>
|
||
<div class="col-lg-3 col-12 centered-lg">
|
||
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
||
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
||
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
||
</div>
|
||
</div>
|
||
<div class="row">
|
||
<div class="col-lg-12 centered-lg">
|
||
<nav class="bottom-links">
|
||
<ul class="mt-3">
|
||
<li>
|
||
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
||
</li>
|
||
</ul>
|
||
</nav>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK606100&ncbi_domain=statpearls&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK606100/&ncbi_pagename=Angiotensin Receptor Blockers and HCTZ Combination Drugs - StatPearls - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |